SCHEMBL6723395

SCHEMBL6723395

Cc1ccccc1NC(=O)C(Cc1ccccc1)NC(=S)Nc1ccccc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.53
▸ MEN1 O00255 5/20 0.53
▸ KMT2A Q03164 5/20 0.53
▸ LMNA P02545 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ RAB9A P51151 3/20 0.48
▸ MAPT P10636 3/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ POLB P06746 1/20 0.47
▸ GAA P10253 1/20 0.46
▸ TACR1 P25103 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ ALOX12 P18054 1/20 0.45
▸ HTT P42858 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ CCR6 P51684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716241 0.86 SMN1; SMN2 (0.55) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6717430 0.82 ALDH1A1 (0.59) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6713812 0.82 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6716834 0.82 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL29776969 0.81 L3MBTL1 (0.59) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6723929 0.81 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6713938 0.81 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6716851 0.81 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL29776967 0.79 HPGD (0.53) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6717225 0.76 MAPT (0.58) ALDH1A1MEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 — — US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 — — WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885MEN1 2933/4885KMT2A 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback